An experimental gene-editing treatment dramatically lowered cholesterol levels — maybe permanently — after one infusion, a preliminary study found.
The study, published May 25 in The New England Journal of Medicine, gave 35 patients six doses of VERVE-102, an investigational base-editing therapy that deactivates proprotein convertase subtilisin-kexin type 9 in the liver. People with loss-of-function variants of PCSK9 have reduced levels of LDL cholesterol and fewer atherosclerotic cardiovascular disease events.
A single infusion of the highest dose reduced LDL cholesterol levels by up to 62%, and the change has lasted for patients who were treated 18 months ago.
This preliminary study will be followed by a larger study of 200 patients, The New York Times reported May 25.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
